Our Position on Peptides: Why Vitalis-Health Focuses on Foundations First

Ryan Bentley, MD, PhD, DC  &  Carley Dykstra, PA  |  Vitalis-Health  |  Holland, Michigan  |  March 22, 2026

Peptides are everywhere right now. Scroll through social media for five minutes and you will see claims that they reverse aging, build muscle, burn fat, heal your gut, and sharpen your brain. Some of these claims have real science behind them. Most do not. And the gap between what peptides can do in a controlled research setting and what is being sold to you from a gray-market website is enormous.

Patients ask us about peptides every week. They want to know why we are not offering BPC-157 injections like the clinic down the street. They want to know if we are behind the curve. The short answer: we are not behind anything. We are ahead of it. And this article explains why.

What Peptides Actually Are

A peptide is simply a short chain of amino acids. Your body produces thousands of them every day. They act as signaling molecules, telling your cells what to do, when to do it, and how aggressively to respond.

Here is the part that surprises most people: some of the most commonly prescribed medications in medicine right now are peptides. Insulin is a peptide. The GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are peptides. These are FDA-approved, rigorously tested drugs prescribed by physicians every single day.

So when a physician says “I do not believe in peptides,” that statement does not hold up. You already prescribe them. The question is not whether peptides work. The question is which peptides have sufficient evidence, which ones can be legally and safely obtained, and whether they address the actual root cause of what is making someone sick.

The Peptides Everyone Is Talking About

The peptides generating the most excitement in the biohacking and longevity space are compounds like BPC-157 (Body Protection Compound), TB-500 (Thymosin Beta-4), CJC-1295, Ipamorelin, and AOD-9604. These are not the FDA-approved peptides mentioned above. None of these compounds has ever been approved by the FDA for any human use.¹

BPC-157 has roughly 200 published studies, nearly all in animal models. The preclinical data on tissue repair, gut healing, and anti-inflammatory effects is genuinely interesting. We follow this research closely. But interesting preclinical data is not the same as proven, safe, and ready for clinical use in humans. We have seen promising animal data fail to translate to humans more times than any of us can count.

The human clinical trial data on BPC-157 is almost nonexistent. The single Phase I trial that was registered appears to have been stopped or cancelled without published results.² That absence of data matters. It does not mean the compound is dangerous. It means we do not know enough to make confident clinical decisions about dosing, safety, drug interactions, or long-term effects.

The Legal Reality Most Clinics Will Not Tell You

In September 2023, the FDA placed 17 popular peptides, including BPC-157, on its Category 2 bulk drug substances list. Category 2 means the FDA has identified safety concerns and does not permit compounding pharmacies to prepare these substances for human use under current regulations.³

This is not a gray area. Licensed compounding pharmacies in the United States cannot legally compound BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, or the other Category 2 peptides for patients.⁴ The Department of Justice prosecuted Tailor Made Compounding LLC for distributing unapproved peptides including BPC-157. The company pleaded guilty and forfeited $1.79 million.⁵

So where are clinics getting them? Most are sourcing from online vendors that sell peptides labeled “for research purposes only” or “not for human consumption.” Everyone involved understands what these products are actually being used for. The “research only” label is a legal fiction designed to create distance between the seller and the FDA.⁶

Here is what patients need to understand about this arrangement. When a physician prescribes or recommends a substance from one of these sources, most malpractice insurance policies will not cover them. Prescribing an unapproved drug from an unregulated source falls outside the standard of care. If something goes wrong, the physician is likely self-insuring that risk, and the patient has limited recourse.⁷

State Medical Boards are paying attention. The FDA and DOJ are actively enforcing. In June 2025, FDA agents raided one of the largest gray-market peptide vendors, shutting it down overnight.⁸ This is not a theoretical risk. It is happening now.

There is another problem that rarely gets discussed. Even if a clinic can source these peptides today, there is no guarantee of continued access tomorrow. Regulations shift. Suppliers disappear overnight. Gray-market vendors get shut down without warning. If we build your treatment plan around a substance we cannot reliably obtain through a regulated supply chain, we have not given you a protocol. We have given you a dependency on something we cannot sustain. That is not a long-term treatment plan. At Vitalis-Health, we do not put patients on therapies that can be pulled out from under them without notice.

What About the Recent Announcement?

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on a podcast that approximately 14 of the 19 restricted peptides would be moved back to Category 1, restoring legal compounding access through licensed pharmacies with a physician’s prescription.⁹

This is a significant statement. It is not, however, a completed regulatory action. As of this writing (March 2026), the FDA has not published an updated list. No formal reclassification has been finalized. Political commentary and regulatory action are not the same thing.¹⁰

If and when certain peptides return to Category 1, that means licensed compounding pharmacies can prepare them under a physician’s prescription. It does not mean they become FDA-approved drugs. It does not mean they have completed clinical trials. It does not mean the evidence base has changed. It means the legal supply chain reopens under medical supervision. That is a meaningful step, and we will evaluate each compound on its merits when the regulatory picture clarifies.

We will update this position if and when formal FDA action occurs. Until then, we will not recommend substances to our patients based on a podcast announcement.

You Cannot Out-Peptide a Bad Foundation

This is the part of the conversation that matters most, and it is the part that gets lost in the peptide excitement.

At the cellular level, every chronic health problem we see at Vitalis-Health comes down to one of two things: something is there that should not be (toxicity), or something is missing that should be there (deficiency). And this applies on every level: physical, chemical, and emotional. A toxic relationship or unresolved emotional trauma disrupts your physiology just as surely as lead in your bloodstream. A body that never moves is physically deficient in the stimulus it was designed to receive. The whole system works together.

You cannot out-peptide a bad lifestyle. You cannot out-supplement a toxic environment. You cannot inject your way past a diet that is starving your mitochondria of the nutrients they need to produce energy. And you cannot skip the fact that your body was made to move. Regular movement is not optional. It is as foundational as the food you eat and the air you breathe.

Health and longevity are not built on the latest hack or trend. They are built on daily habits. Are you sleeping seven to eight hours? Are you managing your stress or just surviving it? Are you eating real food that gives your cells what they need? Are you moving your body every day? These are not glamorous questions, but they are the ones that determine whether your body functions or fails. Get these right, and your body responds. Skip them in favor of the newest injectable, and you are building on sand.

The foundation comes first. Always. Before peptides, before biohacks, before any trend that promises a shortcut. Optimize sleep, nutrition, movement, and stress management. Then, if there is still a gap, we have tools to address it.

What Vitalis-Health Actually Does

Our clinical approach starts with a comprehensive assessment. We need to understand where you sit on the spectrum from health to disease before we can determine the right plan. Think of it this way. If the house is on fire, you do not start by repairing the foundation. You put the fire out first. Sometimes that means medication. Sometimes that means therapeutic plasma exchange to mechanically remove the inflammatory mediators, autoantibodies, or environmental toxins that are driving the crisis. We meet you where you are. Once the fire is out, we rebuild the foundation so the house does not catch fire again.

How we assess and where we start.

Every patient begins with a thorough traditional workup. We run a comprehensive metabolic panel, complete blood count, thyroid panel, lipid panel, and any other standard labs the clinical picture demands. If those labs come back essentially normal and you are still symptomatic, that is not the end of the conversation. That is where most of medicine stops. It is where we start going deeper.

From there, we look at what standard panels do not measure. We measure your toxic burden: PFAS, heavy metals, mycotoxins, pesticides, and other environmental chemicals that accumulate in your tissues and disrupt cellular function. We run genetic testing to identify variants in methylation, detoxification, and nutrient metabolism pathways. We also look at intracellular nutrient status, not just serum levels, because what is in your blood is not always what is in your cells.

We remove what does not belong.

Therapeutic plasma exchange allows us to mechanically remove protein-bound toxins, inflammatory mediators, autoantibodies, and circulating aging factors directly from the bloodstream. A single TPE session removes approximately 60 to 70 percent of these circulating substances. This is not a supplement claiming to support detoxification. It is measured, objective removal confirmed by pre- and post-treatment lab work.

We replace what is missing.

After identifying your specific genetic vulnerabilities and nutrient gaps, we build repletion protocols tailored to your biochemistry. Nearly half the population carries BCMO1 variants that reduce the efficiency of converting beta-carotene to active vitamin A. Once identified, the fix is straightforward: preformed retinol from animal sources or targeted supplementation. That is precision medicine. That is what moves the needle.

We use medications when the situation demands them.

This includes FDA-approved peptide medications when appropriate. GLP-1 receptor agonists for metabolic syndrome and insulin resistance. Medications are tools, and sometimes they are the right tool to put out the fire while we rebuild the foundation.

Our Promise to You

We will never knowingly recommend a therapy to you that we cannot obtain through a legal, regulated supply chain. We will never knowingly expose you to a substance where we cannot verify purity, potency, and safety. We will never knowingly chase a trend at the expense of your trust.

But here is what will not change: our insistence on starting with a thorough assessment, meeting you where you are on the health-to-disease spectrum, and addressing the root causes. Remove the toxicity. Fix the deficiencies. Identify your genetic vulnerabilities so they stop being invisible liabilities and start being actionable information. Give your cells a clean environment and the right raw materials. Move your body the way it was designed to move. Then, and only then, do we consider adding tools on top of that foundation.

That is not a conservative approach. It is the most effective one. And it is the one your cells have been waiting for.

Questions about peptides or precision medicine? Call us at 616-294-3211 or visit vitalis-health.com.

---

References

1. FDA Category 2 Bulk Drug Substances List. FDA.gov
2. USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. September 2025. USADA.org
3. FDA Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. Category 2 designation, September 2023.
4. Holt Law. Regulatory Status of Popular Compounded Peptides. djholtlaw.com
5. FDA OCI. Nicholasville Compounding Pharmacy Pleads Guilty. October 2020. FDA.gov
6. Holt Law. Peptide Legal FAQ. djholtlaw.com
7. Holt Law. The Unregulated World of Peptides. djholtlaw.com
8. Peptide Examiner. Why Did Peptide Sciences Close Down? March 2026. pepexaminer.com
9. The Joe Rogan Experience, Episode #2461 with Robert F. Kennedy Jr. February 27, 2026.
10. LumaLex Law. RFK Jr, Peptides & FDA Category 2. March 2, 2026. lumalexlaw.com